Despite constant improvement in existing therapeutic efforts, the overall survival rate of lung cancer patients remains low. Enzyme activities may identify new therapeutically targetable biomarkers and overcome the marked lack of correlation between cellular abundance of translated proteins and corresponding mRNA expression levels. We analysed tyrosine kinase activities to classify lung adenocarcinoma (LuAdCa) resection specimens based on their underlying changes in cellular processes and pathways that are agents of or result from malignant transformation. We characterised 71 same-patient pairs of early-stage LuAdCa and non-neoplastic LuAdCa resection specimen lysates in the presence or absence of a tyrosine kinase inhibitor. We performed ex vivo multiplex tyrosine phosphorylation assays using 144 selected microarrayed kinase substrates. The obtained 76 selected phosphotyrosine signature peptides were subsequently analysed in terms of follow-up treatments and outcomes recorded in the patient files. For tumour, node, metastasis (TNM) stage 1 LuAdCa patients, we noticed a larger tyrosine kinase inhibitor-induced decrease in tyrosine phosphorylation for long-term as opposed to short-term disease survivors, for which 26 of 76 selected peptides were significantly (p < 0.01, FDR < 3%) more inhibited in the long-term survivors. Using statistical class prediction analysis, we obtained a 'prognostic-signature' for long- versus short-term disease survivors and correctly predicted the survival status of 73% of our patients. Our translational approach may assist clinical disease management after surgical resection and may help to direct patients for an optimal treatment strategy.

Cordyceps militaris is a valuable medicinal mushroom that contains numerous bioactive ingredients such as cordycepin, adenosine, pentostatin, polysaccharides, and carotenoids. However, the contents of these substances in wild-type strains of C. militaris are relatively low. Recently, the genome of C. militaris has been fully sequenced, and genes involved in the biosynthesis of beneficial constituents have been identified. Therefore, research on enhancing the biosynthesis of the bioactive compounds in this fungus by recombinant DNA technology has advantages. In the present study, the authors have successfully generated a binary vector with a T-DNA region carrying a construct regulated by the native rpb1 promoter that can enhance gene expression in C. militaris. The T-DNA structure from the binary vector was then transferred into the C. militaris genome by Agrobacterium tumefaciens-mediated transformation. Analysis of some fungal transformants by PCR using the specific primer pairs indicated that the T-DNA structure was successfully integrated into the fungal genome. Observation of the transformants under fluorescence microscopy confirmed the overexpression of the DsRed fluorescent protein under the regulation of the rpb1promoter. The binary vector carrying the rpb1 promoter constructed in this study can be employed to promote the expression of target genes in the medicinal mushroom C. militaris.

Carbamazepine (CBZ) is a commonly prescribed drug for patients with epilepsy. However, after administration of CBZ, many patients experience cutaneous adverse drug reactions (CADRs), the most common allergic skin symptoms. CYP2D6 enzyme is one of the enzymes that play an important role in drug metabolism in general and CBZ in particular. Therefore, analysis of gene expression and enzyme activity of CYP2D6will help predict the magnitude of CBZ metabolism of the patients, allowing them to forecast CADRs. In this study, the authors evaluated the mRNA expression of CYP2D6 in CBZ-treated epilepsy patients using a Real-time PCR method, and then investigated the relationship of CYP2D6 expression levels between mild and severe CADR harbouring groups. The results showed that the expression level of CYP2D6 in the CBZ-tolerant group was about 3 times higher than that in the CBZ-allergic group. These results suggested that the gene expression level of CYP2D6 could be a useful biomarker for predicting CBZ response in patients with epilepsy.